Compare ACDC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | PHVS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.3B |
| IPO Year | 2021 | 2020 |
| Metric | ACDC | PHVS |
|---|---|---|
| Price | $5.97 | $32.73 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $5.50 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.4M | 291.1K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,941,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $16.72 |
| 52 Week High | $8.49 | $34.41 |
| Indicator | ACDC | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 60.08 |
| Support Level | $5.98 | $24.73 |
| Resistance Level | $7.92 | $33.33 |
| Average True Range (ATR) | 0.66 | 1.60 |
| MACD | -0.12 | 0.18 |
| Stochastic Oscillator | 12.13 | 72.94 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.